We are live on ! Find out more
GP

Geneva Partners Portfolio holdings

AUM $375M
1-Year Est. Return 131.24%
This Fund
S&P 500
This Quarter Est. Return
+63.68%
1 Year Est. Return
+131.24%
3 Year Est. Return
+400.69%
5 Year Est. Return
+687.84%
10 Year Est. Return
–
AUM
$375M
AUM Growth
+$167M
Cap. Flow
+$78.9M
Cap. Flow %
21.04%
Top 10 Hldgs %
41.06%
Holding
81
New
18
Increased
32
Reduced
22
Closed
6

Top Buys

Rank Stock Value
1
MRVL icon
Marvell Technology
MRVL
+$13.6M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$12.8M
3
TER icon
Teradyne
TER
+$10.8M
4
GLW icon
Corning
GLW
+$9.04M
5
BE icon
Bloom Energy
BE
+$7.64M

Top Sells

Rank Stock Value
1
VHT icon
Vanguard Health Care ETF
VHT
+$8.04M
2
LLY icon
Eli Lilly
LLY
+$3.76M
3
ORLY icon
O'Reilly Automotive
ORLY
+$3.49M
4
HSY icon
Hershey
HSY
+$2.69M
5
AAOI icon
Applied Optoelectronics
AAOI
+$2.5M

Sector Composition

Rank Sector Weight
1 Technology 41.44%
2 Miscellaneous 22.43%
3 Industrials 20.38%
4 Communication Services 5.93%
5 Energy 4.18%

No holdings matched the selected filter criteria.

1 2 3 4

Similar funds

PCM
Payne Capital Management New York $375M AUM 22.8% 1-Year Est. Return
FLI
Family Legacy Inc Greenville, South Carolina $375M AUM 35.98% 1-Year Est. Return
CCM
Consolidated Capital Management Burbank, California $375M AUM 54.27% 1-Year Est. Return
SBF
Sara-Bay Financial Sarasota, Florida $375M AUM 56.53% 1-Year Est. Return
SPFSPD
Sava Pension Fund (Sava Penzisko Drushtvo) Skopje $375M AUM 25.78% 1-Year Est. Return
HIC
Harbor Island Capital Topsfield, Massachusetts $376M AUM 128.24% 1-Year Est. Return
WIC
WealthBridge Investment Counsel Calgary, Alberta, Canada $375M AUM 37.9% 1-Year Est. Return
BAM
Bell Asset Management Melbourne, Australia $375M AUM 3.54% 1-Year Est. Return

Geneva Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Geneva Partners held 81 positions worth $375M, up 80% from $208M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Geneva Partners deployed $78.9M of net new capital in Q2 2026, opening 18 new positions and adding to 32 existing holdings. Its largest new stake was Marvell Technology: 68,048 shares worth $20.3M.

By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 24% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Eli Lilly, an estimated $3.76M trimmed.

  • Geneva Partners's largest Q2 2026 buy was Marvell Technology: 68,048 shares worth $20.3M.
  • Geneva Partners added most to Dell in Q2 2026, an estimated $4.08M increase.
  • Geneva Partners's biggest Q2 2026 reduction was Eli Lilly, cutting an estimated $3.76M.
  • Geneva Partners fully exited Vanguard Health Care ETF in Q2 2026, selling an estimated $8.04M.
  • Geneva Partners's ten largest holdings make up 41% of its $375M portfolio in Q2 2026.
  • Geneva Partners opened 18 new positions and closed 6 in Q2 2026.
  • Geneva Partners's portfolio value rose 80% quarter-over-quarter to $375M.

Based on Geneva Partners's 13F filing for Q2 2026, filed 10 Aug 2026.